These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35133884)

  • 1. Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study.
    Saito T; Sugimoto S; Sakaguchi R; Nakamura H; Ishigooka J
    J Child Adolesc Psychopharmacol; 2022 Feb; 32(1):12-23. PubMed ID: 35133884
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-Term Safety and Efficacy of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 52-Week, Multicenter, Open-Label Extension Study.
    Saito T; Hyodo Y; Sakaguchi R; Nakamura H; Ishigooka J
    J Child Adolesc Psychopharmacol; 2022 Feb; 32(1):24-35. PubMed ID: 34612724
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study.
    Iwata N; Ishigooka J; Naoi I; Matsumoto M; Kanamori Y; Nakamura H; Higuchi T
    CNS Drugs; 2020 Jan; 34(1):103-116. PubMed ID: 31883082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study.
    Iwata N; Ishigooka J; Kim WH; Yoon BH; Lin SK; Sulaiman AH; Cosca R; Wang L; Suchkov Y; Agarkov A; Watabe K; Matsui T; Sato T; Inoue Y; Higuchi T; Correll CU; Kane JM
    Schizophr Res; 2020 Jan; 215():408-415. PubMed ID: 31471246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.
    Garcia E; Robert M; Peris F; Nakamura H; Sato N; Terazawa Y
    CNS Drugs; 2009; 23(7):615-25. PubMed ID: 19552488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study.
    Harvey PD; Nakamura H; Miura S
    Neuropsychopharmacol Rep; 2020 Mar; 40(1):63-72. PubMed ID: 31788985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study.
    Goldman R; Loebel A; Cucchiaro J; Deng L; Findling RL
    J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):516-525. PubMed ID: 28475373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8-week, double-blind, multicenter, randomized controlled study.
    Harvey PD; Nakamura H; Murasaki M
    Neuropsychopharmacol Rep; 2019 Sep; 39(3):173-182. PubMed ID: 31041855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial.
    Findling RL; McKenna K; Earley WR; Stankowski J; Pathak S
    J Child Adolesc Psychopharmacol; 2012 Oct; 22(5):327-42. PubMed ID: 23083020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial.
    Li H; Yao C; Shi J; Yang F; Qi S; Wang L; Zhang H; Li J; Wang C; Wang C; Liu C; Li L; Wang Q; Li K; Luo X; Gu N
    J Psychiatr Res; 2015 Oct; 69():102-9. PubMed ID: 26343601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials.
    Kishi T; Matsuda Y; Nakamura H; Iwata N
    J Psychiatr Res; 2013 Feb; 47(2):149-54. PubMed ID: 23131856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
    Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
    Findling RL; Robb A; Nyilas M; Forbes RA; Jin N; Ivanova S; Marcus R; McQuade RD; Iwamoto T; Carson WH
    Am J Psychiatry; 2008 Nov; 165(11):1432-41. PubMed ID: 18765484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.
    Bugarski-Kirola D; Iwata N; Sameljak S; Reid C; Blaettler T; Millar L; Marques TR; Garibaldi G; Kapur S
    Lancet Psychiatry; 2016 Dec; 3(12):1115-1128. PubMed ID: 27816567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia.
    Findling RL; Landbloom RP; Mackle M; Pallozzi W; Braat S; Hundt C; Wamboldt MZ; Mathews M
    J Child Adolesc Psychopharmacol; 2015 Jun; 25(5):384-96. PubMed ID: 26091193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
    Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
    J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
    Kane JM; Peters-Strickland T; Baker RA; Hertel P; Eramo A; Jin N; Perry PP; Gara M; McQuade RD; Carson WH; Sanchez R
    J Clin Psychiatry; 2014 Nov; 75(11):1254-60. PubMed ID: 25188501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan.
    Kishi T; Ikuta T; Sakuma K; Okuya M; Iwata N
    J Psychiatr Res; 2021 Jun; 138():444-452. PubMed ID: 33964682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Striatal Dopamine D2 Receptor Occupancy Induced by Daily Application of Blonanserin Transdermal Patches: Phase II Study in Japanese Patients With Schizophrenia.
    Nishibe H; Tateno A; Sakayori T; Yamamoto M; Kim W; Kakuyama H; Okubo Y
    Int J Neuropsychopharmacol; 2021 Feb; 24(2):108-117. PubMed ID: 32936897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.